

**OMTN, Volume 9**


**Supplemental Information**

**Size, Shape, and Sequence-Dependent  
Immunogenicity of RNA Nanoparticles**


**Sijin Guo, Hui Li, Mengshi Ma, Jian Fu, Yizhou Dong, and Peixuan Guo**

## SUPPLEMENTAL INFORMATION:


### Supplemental Figures:



**Figure. S1.** Step-wise self-assembly of small, medium and large 2'F SQR-SEQ, 2'F TRI-SEQ, 2'F PENTA-SEQ and 2'F Tetrahedron-SEQ evaluated by 3% agarose gel (M=monomer, D=dimer, T=trimer, Tetra=tetramer, P=pentamer; ladder: 100 bp DNA).




**Figure. S2.** Flow cytometry analysis showing the increased cellular binding of medium 2'F SQR-SEQ to RAW 264.7 cells as more copies of 2'F SEQ incorporated (2'F SQR-2 SEQ refers to 2'F Square with two SEQ extensions on the neighboring vertexes, and 2'F SQR-2' SEQ means 2'F Square with two SEQ extensions on the opposite vertexes).



**Figure. S3.** Size distribution histogram of 2'F Tetrahedron (Th)-SEQ measured by DLS (n=3).

### Comparison of 2'F SQR-SEQ and 2'F SQR-double-stranded SEQ



**Figure. S4.** Cytokines **a.** TNF- $\alpha$  and **b.** IL-6 induction by medium 2'F SQR-SEQ, 2'F SQR-double-stranded SEQ and control groups (concentrations refer to nanoparticles; results were presented as mean $\pm$ standard deviation, n=3, \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , analyzed by student's t test).

**Table S1.** Sequences for primary RNA nanoparticles (5'→3')

SEQ (20nt)	UCCAUGACGUUCCUGACGUU
Mutated SEQ I (20nt)	UCCAUGAGCUUCCUGACGUU
Mutated SEQ II (20nt)	UCCAUGAGCUUCCUGAGCUU
Scramble sequence(20nt)	GCAGCUUUGGCUGAGCGUAU
Complementary SEQ (20nt)	AACGUCAGGA ACGUCAUGGA
Small SQR A-SEQ (63nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGACCGU ACUUUGUUGCACGCC
Small SQR B-SEQ (63nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGACCCAAUCAUGUCUCU ACUUUGUUGGCUGGCC
Small SQR C-SEQ (63nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGCCAGCCAAUCAUGCACAU ACUUUGUUGACGGCCC
Small SQR D-SEQ (63nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGUAGUU ACUUUGUUGGGUCGCC
Small SQR E (48nt)	GGUCAUGUGUAUGUGCAUGUGUAGAGACAUGUGUAACUACAUGUGU AC
Medium SQR A-SEQ (73nt) TRI A-SEQ (73nt) PENTA A-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGGCAAG UGUCCGCCAUACUUUGUUGCACGCC
Medium SQR B-SEQ (73nt) PENTA B-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGACCCAAUCAUGGCAAC GAUAGAGCAUACUUUGUUGGCUGGCC
Medium SQR C-SEQ (73nt) TRI C-SEQ (73nt) PENTA C-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGCCAGCCAAUCAUGGCAAU AUACACGCAUACUUUGUUGACGGCCC
Medium SQR D-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGACAAG CGCAUCGCAUACUUUGUUGGGUCGCC
Medium SQR E (88nt)	GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA UCGUUGUCAUGUGUAUGCGAUGCGCUUGUCAUGUGUAUGGC
TRI B-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGGCAAC GAUAGAGCAUACUUUGUUGGCUGGCC
TRI D (66nt)	GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA UCGUUGUCAUGUGUAUGGC
PENTA D-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGCCCUCAAUCAUGGCAAG CGCAUCGCAUACUUUGUUGGGUCGCC

PENTA E-SEQ (73nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGGCAAA UAUGCGCCAUACUUUGUUGUAGGGCC
PENTA F (110nt)	GGACACUUGUCAUGUGUAUGCGUGUAUAUUGUCAUGUGUAUGCUCUA UCGUUGUCAUGUGUAUGCGAUGCGCUUGUCAUGUGUAUGGGCGCAUAU UUGUCAUGUGUAUGGC
Large SQR A-SEQ (93nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCGUCAAUCAUGGCAAG UGUCCGCAAGCAUAGCUCGGAUAGCCUCAUACUUUGUUGCACGCCC
Large SQR B-SEQ (93nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGACCCAAUCAUGGCAAC GAUAGAGGCAUAGUCGACCUAUGCAUCCAUAUACUUUGUUGGCUGGCC
Large SQR C-SEQ (93nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCCAGCCAAUCAUGGCAAU AUACACGCGAGUUGCCACGAGGACGCUCAUACUUUGUUGACGGCCC
Large SQR D-SEQ (93nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCGUGCAAUCAUGACAAG CAUCGCAUUCGGUGUCGUAGUCCUUCGCAUACUUUGUUGGGUCGCC
Large SQR E (168nt)	GGACACUUGUCAUGUGUAUGAGCGUCCUCGUGGCAACUCGCGUGUAU AUUGUCAUGUGUAUGGAUGCAUAGGUCGACUAUGCCUCUAUCGUUGU CAUGUGUAUGCGAAGGACUACGACACGGAAUGCGAUGCUUGUCAUGU GUAUGAGGCUAUCCGAGCUAUGCUUGC
Th A-SEQ (115nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGACUGAUACGAAUCAUCGU GUAGCACCAGCUGUAAUCGAUGUGUACGGGAAGAGCCUAUGCCCAUC CUACUUUGUUCUACUAUGGCG
Th B-SEQ (115nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGUGCUACACGAUGUGUAGC CAGACUUAGCGGAAUGUUCGUACUUUGUUCAUGCGAGGCCGUCCAAU ACCGAAUCAUCGAUUACAGCU
Th C-SEQ (115nt)	GGUCCAUGACGUUCCUGACGUUUUUUUGGGCAGUUGAGAUGUGUACG AACAUUCCGCUAAGUCUGGCUACUUUGUUCGUAUCAGUCCCGCCAUA GUAGAAUCAUCGUAUCACCAU
Th D (88nt)	GGCCUCGCAUGAAUCAUCUCAACUGCCCAUGGUGAUACGAUGUGUAG GAUGGGCAUAGGCUCUCCCGUACUUUGUUCGGUAUUGGAC
RNA SQR (small, medium & large)	Reference (54)
RNA TRI, SQR & PENTA	Reference (59)
RNA Th	Reference (43)

(SEQ: specific sequence, TRI: triangle, SQR: square, PENTA: pentagon, Th: tetrahedron)

## **Supplemental Methods:**

### **Flow Cytometry Assay**

$5 \times 10^5$  RAW 264.7 cells were suspended in Opti-MEM medium in 1.5mL eppendorf tubes. Cy3-labeled RNA nanoparticles were diluted in Opti-MEM medium at 100nM and incubated with cells at 37 °C for 1.5 hours. After washing with PBS buffer (137 mM NaCl, 2.7 mM KCl, 100 mM Na<sub>2</sub>HPO<sub>4</sub>, 2 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) to remove unbound nanoparticles, cells were re-suspended in PBS buffer and the cell binding efficacy was determined by FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).